Here are six drug and medical device companies that made headlines in the past week.
1. Pfizer hits J&J with 1st ever biosimilar antitrust lawsuit: 4 things to know
Pfizer on Wednesday filed an antitrust suit against Johnson & Johnson, claiming the drugmaker's "exclusionary contracts" with insurers and hospitals unfairly blocked competition for J&J's arthritis drug Remicade.
2. Teva to sell remaining women's health assets in 2 deals totaling $1.38B
Israel-based Teva Pharmaceuticals will sell its remaining women's health assets in two deals, totaling $1.38 billion.
3. Express Scripts CMO: Healthcare system isn't set up to pay for Novartis' $475k cancer drug
Giving patients access to Novartis' $475,000 breakthrough leukemia therapy — an extremely expensive but highly effective treatment — is going to take novel collaboration, according to Express Scripts CMO Steve Miller, MD.
4. House Reps. call on Merck to disclose Petya damage, response
Two Republicans on the House Energy and Commerce Committee requested Kenneth Frazier, CEO of Kenilworth, N.J.-based Merck, release an update on the lingering effects of a June malware attack, which they alleged could lead to a drug shortage.
5. Spectranetics recalls nearly 2k catheters
Spectranetics recalled more than 1,900 Bridge Occlusion Balloon Catheters over a product flaw that may prevent the device from working properly.
6. Alaska union-benefits fund sues Abbott over faulty St. Jude defibrillators
An Alaska union-benefits fund filed a federal lawsuit against Abbott Laboratories, claiming the company' subsidiary, St. Jude Medical, failed to warn regulators and patients about defective lithium batteries in its defibrillators for years.
More articles on supply chain:
FDA takes action against 500 websites illegally selling prescription medicine
Medline director of sales Brian Garner on the impact of mobility on a patient's confidence
FDA: Major drug shortages possible after Hurricane Maria